Zhitong Finance App News, Yuandong Biology (688513.SH) announced that the first-class chemical innovation drug EP-0226 tablets jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute are undergoing a multi-center, randomized, double-blind, double-blind, double-simulation, placebo and pregabalin capsules in patients with post-herpes zoster neuralgia in China. Recently, the first case of patient administration was completed.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Yuandong Biology (688513.SH) announced that the first-class chemical innovation drug EP-0226 tablets jointly developed by the company, the Shanghai Institute of Pharmaceutical Sciences of the Chinese Academy of Sciences and the Zhongke Zhongshan Pharmaceutical Innovation Research Institute are undergoing a multi-center, randomized, double-blind, double-blind, double-simulation, placebo and pregabalin capsules in patients with post-herpes zoster neuralgia in China. Recently, the first case of patient administration was completed.